Oral antifungal therapy should be prescribed only after confirmation of fungal infection
In general, topical monotherapy can be considered for mild to moderate onychomycosis
MeSH terms Adult Aged Background: The accepted regimen for terbinafine, one of the most effective treatments for dermatophyte onychomycosis, is continuous administration of 250 mg/day over 16 weeks
However, the complete cure rate at 36 weeks after the completion of terbinafine in the original approval study was reported to be only 38 percent, and the great toenail alone was used for outcomes assessments
44, 45 In many cases, itraconazole appears to be more effective Onychomycosis is a chronic infection of the nail unit, and its prevalence increases with age
The optimal clinical effect is seen some months after mycological cure and cessation of treatment
Background: The prevalence of onychomycosis is higher in certain high-risk populations, such as the immunocompromised, diabetics and human immunodeficiency virus (HIV)-positive patients
Objective: To investigate the efficacy and safety of topical terbinafine 10% solution (MOB-015) for the treatment of distal and lateral subungual onychomycosis
Furthermore, the data support the use of terbinafine to treat dermatophyte onychomycosis in children and the elderly
The fungicidal nature of terbinafine and the high concentrations in the nail bed and nail plate after topical application of MOB-015 result in terbinafine levels that are several thousand times greater than the minimum inhibitory concentration for common dermatophytes causing onychomycosis (eg, minimum inhibitory concentration 0
Recent patents related to the management of onychomycosis are also
11 The objective of the present study was to examine long-term mycological and clinical cure rates after treatment with terbinafine and itraconazole The aim of the present investigation was to evaluate microemulsion as a vehicle for dermal drug delivery and to develop microemulsion-based gel of terbinafine for the treatment of onychomycosis